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Understanding lung development has signiﬁcant importance to public health because of the fact that interruptions in the normal
developmental processes can have prominent eﬀects on childhood and adult lung health. It is widely appreciated that the retinoic
acid (RA) pathway plays an important role in lung development. Additionally, PPARs are believed to partner with receptors of
this pathway and therefore could be considered extensions of retinoic acid function, including during lung development. This
review will begin by introducing the relationship between the retinoic acid pathway and PPARs followed by an overview of lung
development stages and regulation to conclude with details on PPARs and the retinoic acid pathway as they may relate to lung
development.
Copyright © 2007 D. M. Simon and T. J. Mariani. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
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1. THE RETINOIC ACID PATHWAY AND PPAR
The eﬀects of retinoic acid are mediated by the retinoic acid
receptors (RAR) and retinoid X receptors (or 9-cis retinoic
acid receptor, RXR). RARs and RXRs each have 3 separate
subtypes: α, β,a n dγ. RXR is speciﬁc for the 9-cis retinoic
acid (9CRA) stereoisomer, while RAR binds both 9CRA and
all-transretinoicacid(ATRA).RARsformheterodimerswith
the three RXR subtypes and RXR’s form heterodimers with
members of the nuclear receptor family, including PPARγ.
RXRs can also form homodimers, which among other ef-
fects, can activate PPAR target genes [1]. While as a group,
the three PPAR isoforms (α, β/δ,a n dγ) function to regu-
late cellular lipid utilization and homeostasis, each isoform
has discrete yet overlapping functions and ligand speciﬁci-
ties. Upon activation by an appropriate ligand, PPARs form
an obligate heterodimer with RXR to recruit nuclear recep-
tor coactivators. Because they function as heterodimers with
the RXR, PPARs could be considered an extension or mod-
ulator of the retinoic acid signaling pathway. The canoni-
cal pathway is that these ligand-activated PPAR-RXR het-
erodimersbindtoperoxisomeproliferatorresponseelements
(PPREs), and activate gene transcription, although PPARs
can also serve as active transcriptional repressors [2]. Fur-
thermore, nongenomic functions of PPARs upon gene regu-
lation (e.g., regulatory eﬀects independent of PPRE binding)
have been reported [3–5]. For instance, PPARs are capable
of trans-repression of other transcription factors, through
direct interaction or through interaction with other coacti-
vator/corepressors. Schupp and colleagues recently demon-
strated that a RARα antagonist can directly aﬀect PPARγ ac-
tivity and therefore be considered both a PPARγ agonist and
RARα antagonist [6]. Additionally, Szatmari and colleagues
found that PPARγ regulates CD1d, a molecule involved in
dendritic cell antigen presentation, by inducing retinoic acid
synthesis through RARα [7] .T h e s eo b s e r v a t i o n sh i g h l i g h t
the complex interplay between nuclear receptors. Given the
numerous pathways through which PPARs could regulate
gene expression either directly or indirectly, it is easy to en-
vision that they may play a role in the complex regulatory
mechanisms of lung development.
2. THE REGULATION OF MAMMALIAN
LUNG DEVELOPMENT
Mammalian lung development follows a highly regulated,
morphogenetic program beginning near mid-gestation and
continuing through postnatal life [8, 9]. The mammalian2 PPAR Research
lung initiates as an out-pouching of the ventral foregut en-
doderm. Initially, during the “embryonic” stage of organ de-
velopment, which occurs during 5th and 6th week of gesta-
tion in the human or embryonic days 9.5 (E9.5) and E10.5
in the mouse, the lung arises as a ventral diverticulum of
the foregut endoderm, separating from the esophagus and
elongating caudally. This bud branches to give rise to the
main bronchi of the left and right lung. Signiﬁcant recent
advanceshavebeenmadeintheunderstandingofthegenetic
and molecularmechanisms governing many of the early pro-
cesses of lung development [10, 11]. Lung bud initiation and
outgrowthiscontrolledbyboththeGli/Shhpathway[12–14]
and FGF receptor signaling [15].
Beginning in the pseudoglandular stage (which occurs
between 6 and 16 weeks of gestation in humans or E10.5–
16.5 in mice) and continuing through the canalicular stage
(which occurs between 16 and 26 weeks of gestation in hu-
mans or E16.5–17.5 in mice), this lung bud subsequently un-
dergoes repeated rounds of dichotomous branching to pro-
duce the tree-like structure of the mature conducting air-
way. Numerous molecules are currently appreciated as play-
ing a role in the branching process. Many, though certainly
not all, of these molecules belong to the BMP and FGF sig-
naling pathways [16–21]. BMP-4 and FGF-10 are believed
to form signaling centers that specify branch initiation sites
and outgrowth [22]. Locations of branching speciﬁcity are
limited, in part, by molecules such as Sprouty and Noggin,
which antagonize FGF and BMP signaling [23, 24]. Many
other factors such as EGF, Shh, and Wnt also play a role
in the regulation of branching morphogenesis. The involve-
ment of these particular pathways also highlights the role
ofepithelial-mesenchymalinteractionsinlungdevelopment.
It is well accepted that epithelial-mesenchymal interactions
are essential for normal lung development, primarily during
embryonic growth and diﬀerentiation [25, 26]. The speciﬁc
role of epithelial-mesenchymal interactions in later stages of
lung development, including postnatal lung maturation, is
unclear. In addition to the continuation of branching mor-
phogenesis, the canalicular stage is marked proximo-distal
cell type speciﬁcation and vascularization.
From 26 to 36 weeks of gestation (E17.5 through postna-
tal day 4 in mice), the “saccular” stage completes formation
of the conducting airway tree and diﬀerentiation of distal ep-
ithelial cells. During this stage, the distal architecture of the
lung dramatically changes due to further diﬀerentiation and
ﬂattening of distal airway epithelia. This process is coordi-
nated by factors such as GATA-6, Nkx2.1, HNF3β, C/EBPα,
glucococorticoid hormones, and FGFs [27]. At or near the




production [28], in coordination with the transcription fac-
tors, Ttf1 and C/EBPα [29]. The calcineurin/NFAT signaling
pathway also appears to play a role in this process [30].
Finally, the gas exchange portions of the lung are formed
during the alveolar stage of development. This occurs begin-
ning in week 36 of human gestation and continues through
earlychildhood. Inmice,thisstageoccursentirely during the
postnatal period, beginning in the ﬁrst week of life and con-
tinuing through the ﬁrst month. Maturation of gas-exchange
capacity involves airway wall secondary crest septation and
elongation, a process referred to as alveogenesis. Elongation
of secondary septae results in partitioning of saccules into
alveolar ducts and alveoli with an increase in gas-exchange
surfacearea. Lung maturation and alveogenesis continues af-
ter birth in both rodents and humans. Although the number
ofairwaygenerationsandbranchingpatternofthelungises-
tablished at birth, the morphology of the lung parenchyma is
quitediﬀerentbetweenthenewbornandtheadult[31].Alve-
oli continue to form for at least 2 years after birth in humans.
Adetailedunderstandingoftheregulatoryprocessescontrol-
ling alveogenesis is lacking. Retinoic acid (discussed further
below), PDGF, and FGF signaling all contribute to the regu-
lation of secondary crest elongation. PDGF-A is essential in
alveolar formation as deﬁned by failed alveogenesis in its de-
ﬁciency state secondary to a lack of development of alveolar
myoﬁbroblasts [32]. FGF signaling is also critical to alveo-
genesis, again, as deﬁned by combined deﬁciency in FGFR3
and FGFR4 [33]. Interestingly, the ligand(s) mediating this
eﬀect is unknown. These data can be integrated into a model
predicting morphogenic gradients of RA and FGF signaling
secondary crest elongation [34]. In recent years, the impor-
tance of coordinated development of the vasculature during
alveolarizationhasgainedappreciation.Itisclearthattheap-
propriate balance of VEGF activity, which is an important
pathway for vascular development and maintenance, plays a
critical role in alveogenesis [35–38]. VEGF also appears to
play a critical role in promoting surfactant expression [39].
Boyden and Tompsett have described a mechanism for
airspace formation distinct from the process of saccule sub-
division by secondary septal elongation; the transformation
of terminal or respiratory bronchioles into alveolar ducts
[31, 40]. Massaro et al. corroborated this concept, ﬁnd-
ing that airspaces can develop through the nutritionally-
dependent elongation of the conducting airway and de novo
formation of alveoli (termed “retrograde alveolarization of
bronchioles”) [41]. Since the time of these seminal observa-
tions, only a few studies have clariﬁed the regulation of alve-
olar duct formation and its contribution to airspace struc-
ture.Intactcollagenand/orelastinﬁbersappearnecessaryfor
the development of alveolar ducts, as treatment of neonatal
rats with the BAPN, an inhibitor of the collagen and elastin
cross-linking enzyme lysyl oxidase results in increased vol-
ume density of alveolar ducts [42]. Indomethacin treatment
of neonatal rats also results in increased alveolar duct forma-
tion, implicating endogenous prostaglandin levels as a regu-
latory component in this process [43].
3. RETINOIC ACID SIGNALING IS ESSENTIAL AT MANY
POINTS IN LUNG DEVELOPMENT
The retinoic acid pathway can have eﬀects on all stages
of lung development (see Figure 1). The RARs and RXRs
have distinct expression patterns, notably during mouse em-
bryonic development [44–47]. Speciﬁcally, RXRs have beenD. M. Simon and T. J. Mariani 3
shown to be expressed in the human lung during critical pe-
riods in development from 13 weeks gestation until term,
then their expression becomes markedly reduced in the adult
[44]. Interestingly, retinoic acid signaling is downregulated
during lung epithelial tubule branching and diﬀerentiation,
which ultimately allows formation of mature type I and II
cells [46, 48].
To understand their functional role, gene-targeted mice
have been generated for all 3 RARs and RXRs [49–51]. RAR
single mutants are viable though they display a range of vi-
tamin A deﬁciency syndromes, which increase when double
null mutants are generated [49, 50]. RXRα loss results in fe-
tal lethality at around E14.5 [52, 53]. Similar to PPARγ null
mutants, these mice display severe myocardial hypoplasia.
Because of the in utero lethality, mice with alleles for con-
ditional gene targeting have been generated [51]. Based on
these studies, RXRα has been found to be a crucial mediator
of metabolism and skin development [54–57]. RXRβ mutant
fetuses also have high mortality (50%) with infertility in vi-
able male pups [58]. RXRγ mutant mice survive and are fer-
tile though they have abnormal metabolism secondary to al-
terations in pituitary-thyroid axis [59, 60]. The development
of these genetically altered mice has provided insight into the
functional role of the RA signaling pathway as it relates to
lung development. Targeted deletion of RARβ alters the reg-
ulation of lung septation [61]. RARγ deletion also results in
reduced elastic tissue and alveolar number with increase in
mean chord length [62]. The authors found similar results
with RXRα deletion. Desai and colleagues demonstrated that
balanced activation of RARα and β is critical for normal lung
bud initiation and endodermal diﬀerentiation [63]. Mollard
and colleagues determined that RA signaling through RARβ
during the pseudoglandular stage promotes the formation of
conducting airways [64]. Because single RAR mutants have
few to no lung abnormalities [61, 64–68], double mutants
have been developed because of the apparent redundancy
in these receptors. For example, RARα/RXRα and RARα/β
doublemutantsdeveloplunghypoplasiaoragenesis[69–71].
Additionally, retinoids are capable of promoting the forma-
tion of alveoli in neonatal rats and in adult rats with elastase-
induced emphysema [72, 73].
4. EPITHELIAL CELL PPARγ EXPRESSION
CONTRIBUTES TO THE REGULATION OF
LUNG MATURATION
Most of the literature regarding the role of PPARs in the
lung has focused on understanding PPARγ. While PPARα
shares the common characteristic of having potent anti-
inﬂammatory properties with PPARγ,i th a sn o tb e e ns h o w n
tohavearoleinregulatinglungdevelopment.Similarly,there
has been no description for a role of PPARβ/δ in modulating
lung development though Matsuura and colleagues demon-
s t r a t e du p r e g u l a t i o no fP P A R β/δ expression in induced hu-
man tracheobronchial epithelial (HBE) cells which suggests
that PPARβ/δ may have a role in the squamous diﬀerenti-
ation process of airway cells [74]. PPARγ is expressed as at
least 2 diﬀerent isoforms, γ1a n dγ2. These isoforms diﬀer
only by the addition of 30 amino acids at the amino termi-
nus of γ2, and appear to be functionally equivalent. While
PPARγ2 is expressed primarily in adipose tissue, PPARγ1
is expressed in a broad range of tissues including the lung,
heart, skeletal muscle, large and small intestine, kidney, pan-
creas, spleen, and breast [5, 75]. Within the lung, PPARγ ex-
pression has been reported in the airway epithelium [76, 77],
b r o n c h i a ls m o o t hm u s c l e[ 76, 78], endothelial cells [79],
macrophages [80], eosinophils [81], and dendritic cells [82].
There is little data describing the expression of PPARγ in
the developing lung. Barlier-Mur and colleagues found that
PPARγ1 mRNA was detectable at 18 days gestation in fetal
rat lungs, as well as the C/EBPs [83]. The expression of these
factors increased during development, peaking just prior to
delivery. While they and others [84]h a v er e p o r t e dP P A R γ
expression in type II alveolar cells, they did not see that this
expression pattern was developmentally regulated, although
it could be induced by exposure of cultured type II alveo-
lar cells to dexamethasone, retinoic acid, EGF, and KGF. In-
terestingly, PPARγ protein concentrations were only induced
by KGF, and not with EGF or dexamethasone. We observed a
spatial and temporally restricted pattern of PPARγ expres-
sion, including prominent immunolocalization within the
conducting airway epithelium of normal mouse lungs [85].
This pattern of staining was ﬁrst detectable at birth and in-
creased in intensity over the ﬁrst few weeks of life in mice.
PPARγ can play a prominent role in regulating cellular
diﬀerentiation. PPARγ is suﬃcient and necessary to promote
the formation of adipocytes and the development of adipose
tissue in vivo [75, 86]. This appears to be due, at least in
part, to the ability of PPARγ to regulate numerous genes in-
volved in lipid metabolism. Complete germ-line PPARγ de-
ﬁciency in mice results in embryonic death at mid gestation,
prior to lung development due to failed placental cytotro-
phoblast diﬀerentiation, which is necessary for placental vas-
cularization [87]. Recently, Duan and colleagues generated a
mouse model of complete PPARγ deﬁciency that spared the
trophoblast, allowing delivery of viable pups that they used
to study the role of PPARγ in the metabolic syndrome [88].
Unfortunately, there was no description of eﬀect on lung de-
velopment. A role for PPARγ in promoting cellular diﬀeren-
tiationisalsosuggestedbyitsantitumoreﬀectsinvivoandin
vitro, which include suppressing cellular proliferation, pro-
moting cell death, and inducing diﬀerentiation of malignant
tumors cells from various organs including the lung [89],
breast [90], colon [91], and adipose tissue [92]. In isolated
lung epithelial cells, PPARγ can promote the expression of
markers for terminal diﬀerentiation including the expression
of surfactant associated protein genes [93–95].
In addition to its roles in cellular diﬀerentiation and or-
gan/tissue development, PPARγ is widely appreciated as a
regulator of tissue inﬂammation, which will be discussed
in other sections of this review. In brief, PPARγ activation
can modulate various immune cell functions. For example,
PPARγ regulates monocyte/macrophage diﬀerentiation and
promotes cellular activation as measured by increased pro-
duction of metalloproteinases and reactive oxygen species
[96]. Dendritic cells express PPARγ, which upon activation4 PPAR Research
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Figure 1: Retinoic acid and PPARγ signaling are essential at many points during lung development. Lung development occurs in multiple
stages (top), each involving critical processes (middle) and multiple regulatory factors. This schematic highlights the timeline for human
lung development, though murine lung development occurs in similar stages. It is widely appreciated that retinoic acid signaling has eﬀects
on all stages of lung development (bottom). Recently, PPARγ has also been found to be a critical modulator of postnatal lung development.
(Adapted from Mariani, T.J. Developmental genetics of the pulmonary system. In: Moody, S.A., Editor, Principles of developmental genetics.
Burlington, VT: Academic Press, 2007:932-945. With the permission of Elsevier Inc.)
can inﬂuence cell maturation and antigenic peptide presen-
tation to T cells [82, 97]. PPARγ is expressed at low lev-
els in resting T cells, but is increased following T cell acti-
vation where PPARγ can then inhibit T cell IL-2 and IFNγ
production [98]. Additionally, PPARγ activation has an an-
tiproliferative and cytotoxic eﬀect on normal and malignant
B cells [99]. While PPARγ expression has been reported in
these various cell types, the target cells and mechanisms for
theprotective, anti-inﬂammatoryactivities ofPPARγ ligands
within the lung are unclear. Some of these inﬂammation-
relatedfunctionsofPPARγ appeartomediate,atleastinpart,
the regulation of resident cell functions. PPARγ has been
shown to be expressed in cultured human airway smooth
muscle cells and its activation inhibits cell growth while in-
ducing apoptosis and inhibits release of GM-CSF and G-CSF
to a greater extent than dexamethasone, a medication fre-
quently used in asthma [78]. Further, in cultured human air-
way epithelial cells, PPARγ activation can inhibit expression
of proinﬂammatory mediators such as TNF-α,I L - 8 ,i N O S ,
and MCP-1 [5, 77, 81].
Our laboratory sought to understand the physiological
role of epithelial cell PPARγ and its potential contribution to
lung development and homeostasis, considering the fact that
PPARγ is capable of having a signiﬁcant and complex inﬂu-
ence upon cellular diﬀerentiation, organ development, and
the control of tissue homeostasis. We hypothesized that ep-
ithelial cell PPARγ might be necessary for the establishment
and maintenance of normal lung structure through regula-
tion of epithelial cell diﬀerentiation and/or control of lung
inﬂammation.
Using a conditional targeting strategy, we deleted the
PPARγ gene speciﬁcally within conducting airway epithe-
lial cells [85]. We started by generating a new line of
CreRecombinase-expressingtargetingmice,termedCCtCre,
where the rat CC10 promoter was used to drive Cre expres-
sion speciﬁcally within the lung conducting airway epithe-
lium. Functional targeting speciﬁcity in these CCtCre mice
wasconﬁrmedbycrossingthemtotheROSA26reporterline.
Crossing the CCtCre mice with mice engineered to have loxP
sites (targets of Cre-mediated recombination) ﬂanking exon
2 of the PPARγ gene led to targeted deletion within the air-
way epithelium (see Figure 2).
Lungs from PPARγ conditionallytargeted,airwayepithe-
lial cell PPARγ deﬁcient mice revealed structural and func-
tional abnormalities at maturity, but not prior to maturity,
including enlarged airspaces consistent with a deﬁciency in
postnatal lung maturation (see Figure 1). Abnormal airspace
structure persists throughout adulthood, but is not progres-
sive and occurs in the absence of inﬂammation. While con-
trol animals show a reduction in mean airspace size between
2 and 8 weeks of age, conditionally targeted, airway epithe-
lial cell PPARγ deﬁcient animals do not. These data suggest
that the phenotype results from an insuﬃciency in postna-
tal lung maturation. This does not appear to be the result
of a defect in alveogenesis, as numerous normal-sized alveoli
exist in conditionally targeted lungs. However, an abnormal
distribution of airspaces, with increased numbers of alveolar
ducts is observed (unpublished observations).
No qualitative or quantitative changes in the major






















































airway epithelium by expressing Cre recombinase under the direction of the rat CC10 promoter (top, left). These mice, termed CCtCre, were
crossed with the ROSA26 Cre reporter mouse to test the eﬃciency for recombining loxP sites in vivo which demonstrated β-galactosidase
staining limited to the conducting airway epithelium (arrow within inset). We crossed the CCtCre mice with mice homozygous for a PPARγ
allele with a pair of loxP sites ﬂanking exon 2 of the gene (top, right) [100], creating mice with PPARγ deﬁciency limited to the conducting
airway epithelium (bottom, left). The conditional targeted genotype was conﬁrmed by identiﬁcation of gene rearrangement speciﬁcally in
the lung alone (bottom, right).
some characteristics of airway epithelial cell diﬀerentiation
appear aﬀected. We found, through genome wide expression
analysis of targeted airway epithelial cells, changes consistent
with alterations in PPARγ function (Lip1, Abca1, and Apoe)
and cellular diﬀerentiation (Moesin, Ctsb, Klf13). We believe
that altered epithelial-mesenchymal interactions, secondary
to epithelial PPARγ deﬁciency, lead to changes in extracellu-
lar matrix gene expression and abnormal lung structure at
maturity. Eﬀorts to further deﬁne the mechanism(s) mediat-
ing this abnormality and to test the role of this transcription
factorinregulatingairwayinﬂammationarethefocusofcur-
rent investigation.
In summary, it is well appreciated that the retinoic acid
signalingpathwaycontributestotheregulationoflungdevel-
opment at many diﬀerent stages, including during terminal
maturation giving rise to the functional gas exchange units
of the lung, the alveoli. Although retinoic acid activity dur-
ing alveogenesis appears to be linked to elastin ﬁber forma-
tion, the cellular and molecular mechanisms for these eﬀects
are not well deﬁned. It has recently become apparent that
PPARγ has a role in contributing to these regulatory pro-
cesses. Again, the mechanisms at work are yet to be deﬁned.
Potentially,theyinvolvetheregulationofepithelialcelldiﬀer-
entiation, and may act in part through interaction with the
RARsandRXRs.Tremendouscurrentactivitiesintheﬁeldof
PPAR biology should rapidly lead to a better understanding
of the role of these transcription factors in promoting lung
maturation and their potential contribution to human lung
disease.
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